Review
doi: 10.1038/nrg963.
Enzyme replacement and enhancement therapies: lessons from lysosomal disorders
Affiliations
- PMID: 12459725
- DOI: 10.1038/nrg963
Item in Clipboard
Review
Enzyme replacement and enhancement therapies: lessons from lysosomal disorders
Nat Rev Genet.
2002 Dec.
Erratum in
- Nat Rev Genet. 2003 Feb;4(2):157.
Abstract
The past decade has witnessed remarkable advances in our ability to treat inherited metabolic disorders, especially the lysosomal storage diseases, a group of more than 40 disorders, each of which is caused by the deficiency of a lysosomal enzyme or protein. During the past few years, both enzyme replacement and enhancement therapies have been developed to treat these disorders. This review discusses the successes and shortcomings of these therapeutic strategies, and the contributions that they have made to treating lysosomal storage diseases.
Similar articles
-
Enzyme replacement therapy for lysosomal storage disorders: successful transition from concept to clinical practice.Mo Med. 2004 Mar-Apr;101(2):100-4. Mo Med. 2004. PMID: 15119106 Review.
-
[Lysosomes and lysosomal storage diseases].J Soc Biol. 2002;196(2):127-34. J Soc Biol. 2002. PMID: 12360741 Review. French.
-
[Enzyme replacement therapy for lysosomal storage disorders].Arch Pediatr. 2011 Oct;18(10):1119-23. doi: 10.1016/j.arcped.2011.07.002. Epub 2011 Aug 27. Arch Pediatr. 2011. PMID: 21873040 Review. French.
-
Gene therapy for the lysosomal storage disorders.Curr Opin Mol Ther. 2002 Aug;4(4):349-58. Curr Opin Mol Ther. 2002. PMID: 12222873 Review.
-
Treatments for lysosomal storage disorders.Biochem Soc Trans. 2010 Dec;38(6):1465-8. doi: 10.1042/BST0381465. Biochem Soc Trans. 2010. PMID: 21118108
Cited by
-
Exosomes as drug delivery vehicles for Parkinson's disease therapy.J Control Release. 2015 Jun 10;207:18-30. doi: 10.1016/j.jconrel.2015.03.033. Epub 2015 Mar 31. J Control Release. 2015. PMID: 25836593 Free PMC article.
-
Lending a helping hand, screening chemical libraries for compounds that enhance beta-hexosaminidase A activity in GM2 gangliosidosis cells.FEBS J. 2007 Oct;274(19):4951-61. doi: 10.1111/j.1742-4658.2007.06040.x. FEBS J. 2007. PMID: 17894780 Free PMC article. Review.
-
Secondary alterations of sphingolipid metabolism in lysosomal storage diseases.Neurochem Res. 2011 Sep;36(9):1654-68. doi: 10.1007/s11064-010-0380-3. Epub 2011 Jan 5. Neurochem Res. 2011. PMID: 21207141 Review.
-
Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses.Curr Pharm Biotechnol. 2011 Jun;12(6):884-96. doi: 10.2174/138920111795542679. Curr Pharm Biotechnol. 2011. PMID: 21235445 Free PMC article. Review.
-
Partial restoration of mutant enzyme homeostasis in three distinct lysosomal storage disease cell lines by altering calcium homeostasis.PLoS Biol. 2008 Feb;6(2):e26. doi: 10.1371/journal.pbio.0060026. PLoS Biol. 2008. PMID: 18254660 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
